Back to Search
Start Over
Thrombocytopenia in antiphospholipid syndrome: Is anticoagulation and/or antiaggregation always required?
- Source :
-
Autoimmunity reviews [Autoimmun Rev] 2024 Jan; Vol. 23 (1), pp. 103417. Date of Electronic Publication: 2023 Aug 22. - Publication Year :
- 2024
-
Abstract
- The antiphospholipid syndrome (APS) is an autoimmune and prothrombotic condition defined by the association of thrombotic events and/or obstetrical complications and the persistence of antiphospholipid antibodies (aPL) over time. Among the new criteria recently included in the 2023 ACR/EULAR classification criteria for APS, thrombocytopenia is one of the most frequent. The occurrence of thrombocytopenia in aPL/APS patients is important to consider because it could predict APS-related clinical events with a 3-fold increased risk for thrombotic events or obstetrical morbidity or all-cause deaths. A debate on the need or not of anticoagulation and/or antiaggregation in APS patients and aPL carriers with thrombocytopenia took place on the 7th edition of the International Congress on Controversies in Rheumatology and Autoimmunity (CORA), that was organized in Turin, Italy, on March 18th, 2023, and this review summarizes the main arguments that were discussed in this session.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2023 Elsevier B.V. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1873-0183
- Volume :
- 23
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Autoimmunity reviews
- Publication Type :
- Academic Journal
- Accession number :
- 37619905
- Full Text :
- https://doi.org/10.1016/j.autrev.2023.103417